Cardiometabolic Disease Market: By Type (Chronic/Congestive Heart Failure, Hypertension, Type II Diabetes, Obesity), By Treatment (ACE Inhibitors, Diuretics, Glucophage, Liposuction, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Cardiometabolic Disease Market size was valued around USD 120.4 Bn in 2022 and is poised to grow at a significant CAGR of 3.8% over 2023-2029. Some of the key factors influencing the market growth include growing demand for a healthy lifestyle as it a crucial for maintenance. Due to rapidly changing lifestyle, food habits and genetic predisposition, rising in the incidence of various diseases such as diabetes, high cholesterol, cardiovascular disease, hypertension and others. Additionally, increasing awareness and government initiatives on public healthcare will fuel the market growth. Huge demand for plants based nutritional products and treatment requires a combination of nourishing, behavioral, and drug treatments, wherein drugs act as an assistant to behavioral therapies. Additionally, increase in acceptance of dietary food supplements and technological advancement in biotechnology for launching new products boosting the market growth. However, lack of awareness among the aged population and lack of standard norms and regulations regarding the medical facilities are some of the factor hinder the market growth. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global cardiometabolic disease market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global cardiometabolic disease market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).

Cardiometabolic Disease Market Key Development:
  • In Oct 2021, Boehringer Ingelheim and Eli Lilly and Company launched CRMSynced, a gamified teaching program that encourages healthcare providers to prioritize a holistic approach to care for cardio-renal-metabolic (C-R-M) problems. Recent advancements in C-R-M treatment and standards have shifted the burden of care to all members of the patient care team, including primary care physicians, specialists, and advanced practice clinicians.
  • In Nov 2021, Novo Nordisk acquired Dicerna Pharmaceuticals including the RNAi research technology platform. Dicerna's expertise in RNAi and oligonucleotide therapeutics, as well as its highly skilled employees, combined with Novo Nordisk's industry leadership in developing and commercializing medicines to treat serious chronic diseases, has the potential to significantly accelerate and expand our mission to deliver GalXC RNAi therapies for the benefit of patients and all of our stakeholders.

Cardiometabolic Disease Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Cardiometabolic Disease Market Dynamics

Cardiometabolic disease slowly leads to numerous various disease such as BP, chronic heart failure central adiposity, and dyslipidemia that increase the risks of patients to suffer from other life threating diseases. Moreover, rising awareness regarding the proper healthcare management fueling the market growth. In addition, high growth in emerging economies provides huge growth opportunity for the market. Increasing number of patients accepting medications and therapeutics due to the spread of digital modes of drug delivery systems will boost the market growth, Further, rising funds and increasing emphasis on the medical sector will fuel the market growth.

Key Features of the Reports

  • The cardiometabolic disease market report provides granular level information about the market size, regional market share, historic market and forecast.
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup's details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market.

Cardiometabolic Disease Market Segmentation

By Type
  • Chronic/Congestive Heart Failure
  • Hypertension
  • Obesity
  • Type II Diabetes
  • Others
By Treatment
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Diuretics
  • Glucophage
  • Liposuction
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
By Geography
  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa (MEA)

Frequently Asked Questions

The CAGR of the cardiometabolic disease market is 3.8% over the forecast period (2023 - 2029)  

AstraZeneca plc, Cardax, Inc., Dicerna Pharmaceuticals, Inc., Eli Lilly and Company    

The Asia Pacific is the fastest-growing region for the cardiometabolic disease market

  1. Executive Summary
  2. Global Cardiometabolic Disease Market Introduction
    • Global Cardiometabolic Disease Market - Taxonomy
    • Global Cardiometabolic Disease Market -Definitions
      • Type
      • Drug Class
      • Distribution Channel
  3. Global Cardiometabolic Disease Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cardiometabolic Disease Market Dynamic Factors - Impact Analysis
    • Global Cardiometabolic Disease Market - Competition Landscape
  4. Global Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Opportunity Analysis
  5. Global Cardiometabolic Disease Market Forecast, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Chronic/Congestive Heart Failure
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Hypertension
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Obesity
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Type II Diabetes
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiometabolic Disease Market Forecast, By Drug Class, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Diuretics
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Glucophage
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Liposuction
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiometabolic Disease Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Hospital Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cardiometabolic Disease Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Region, 2023 - 2029
  2. North America Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Chronic/Congestive Heart Failure
      • Hypertension
      • Obesity
      • Type II Diabetes
      • Others
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Diuretics
      • Glucophage
      • Liposuction
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Country, 2023 - 2029
    • North America Cardiometabolic Disease Market Dynamics - Trends
  3. Europe Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Chronic/Congestive Heart Failure
      • Hypertension
      • Obesity
      • Type II Diabetes
      • Others
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Diuretics
      • Glucophage
      • Liposuction
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Country, 2023 - 2029
    • Europe Cardiometabolic Disease Market Dynamics - Trends
  4. Asia-Pacific Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Chronic/Congestive Heart Failure
      • Hypertension
      • Obesity
      • Type II Diabetes
      • Others
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Diuretics
      • Glucophage
      • Liposuction
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Country, 2023 - 2029
    • Asia-Pacific Cardiometabolic Disease Market Dynamics - Trends
  5. Latin America Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Chronic/Congestive Heart Failure
      • Hypertension
      • Obesity
      • Type II Diabetes
      • Others
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Diuretics
      • Glucophage
      • Liposuction
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Latin America Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Country, 2023 - 2029
    • Latin America Cardiometabolic Disease Market Dynamics - Trends
  6. Middle East and Africa Cardiometabolic Disease Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Chronic/Congestive Heart Failure
      • Hypertension
      • Obesity
      • Type II Diabetes
      • Others
    • Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Angiotensin-Converting Enzyme (ACE) Inhibitors
      • Diuretics
      • Glucophage
      • Liposuction
    • Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
      • Others
    • Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cardiometabolic Disease Market - Opportunity Analysis Index, Type , Drug Class, Distribution Channel, and Country, 2023 - 2029
    • MEA Cardiometabolic Disease Market Dynamics - Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Allergan
      • Alnylam Pharmaceuticals, Inc.
      • Arrowhead Pharmaceuticals, Inc.
      • AstraZeneca plc
      • Biocrates Life Sciences AG
      • Boehringer Ingelheim International GmbH
      • Cardax, Inc.
      • Dicerna Pharmaceuticals, Inc.
      • Eli Lilly and Company
      • Kowa Company, Ltd.
      • Novartis AG
      • Novo Nordisk A/S
      • Roche Holding AG
      • Sanofi S.A.
      • Takeda Pharmaceutical Company Limited
      • United Therapeutics Corporation
  1. Research Methodology
  2. Key Assumptions and Acronyms
  • Allergan
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Biocrates Life Sciences AG
  • Boehringer Ingelheim International GmbH
  • Cardax, Inc.
  • Dicerna Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Kowa Company, Ltd.
  • Novartis AG
  • Novo Nordisk A/S
  • Roche Holding AG
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • United Therapeutics Corporation

Adjacent Markets